sibmedСибирский научный медицинский журналСибирский научный медицинский журнал2410-25122410-2520ИЦиГ СО РАН10.18699/SSMJ20210602sibmed-694Research ArticleОБЗОРЫREVIEWSОсновные направления и перспективы в терапии синдрома поликистоза яичниковThe main directions and prospects in polycystic ovary syndrome treatmenthttps://orcid.org/0000-0003-0725-5455УсеиноваА. Н.UseinovaA. N.

Асие Наримановна Усеинова, к.м.н. 

295051, г. Симферополь, бульв. Ленина, 5/7

Asie N. Useinova, candidate of medical sciences 

295051, Simferopol, Lenin blvd., 5/7

mametova.as@mail.ruhttps://orcid.org/0000-0003-4012-2523ЕгороваЕ. А.EgorovaE. A.

Елена Александровна Егорова, к.фарм.н.

295051, г. Симферополь, бульв. Ленина, 5/7

Elena A. Egorova, candidate of pharmaceutical sciences 

295051, Simferopol, Lenin blvd., 5/7

elena212007@rambler.ruhttps://orcid.org/0000-0002-4731-0263ЕлишеваЕ. А.YelishevaE. A.

Екатерина Александровна Елишева

295051, г. Симферополь, бульв. Ленина, 5/7

Ekaterina A. Yelisheva 

295051, Simferopol, Lenin blvd., 5/7

xxkatexx901@gmail.comhttps://orcid.org/0000-0002-8059-7075БейтуллаевА. М.BeitullaevА. М.

Асан Марленович Бейтуллаев 

295051, г. Симферополь, бульв. Ленина, 5/7

Asan M. Beitullaev 

295051, Simferopol, Lenin blvd., 5/7

asan25.2001@gmail.comhttps://orcid.org/0000-0003-1571-9301КоряноваК. Н.KoryanovaK. N.

Ксения Николаевна Корянова, к.фарм.н.

357532, г. Пятигорск, пр. Калинина, 11

Kseniya N. Koryanova, candidate of pharmaceutical sciences 

357532, Рyatigorsk, Kalinin ave., 11

kskor-16@mail.ruКрымский федеральный университет им. В.И. ВернадскогоРоссияCrimean Federal University n.a. V.I. VernadskyRussian FederationПятигорский медико-фармацевтический институт – филиал Волгоградского государственного медицинского университета Минздрава РоссииРоссияРyatigorsk Medical Pharmaceutical Institute of Volgograd Medical State University of Minzdrav of RussiaRussian Federation2021251220214161829Copyright © Усеинова А.Н., Егорова Е.А., Елишева Е.А., Бейтуллаев А.М., Корянова К.Н., 20212021Усеинова А.Н., Егорова Е.А., Елишева Е.А., Бейтуллаев А.М., Корянова К.Н.Useinova A.N., Egorova E.A., Yelisheva E.A., Beitullaev А.М., Koryanova K.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://sibmed.elpub.ru/jour/article/view/694

Статья посвящена актуальной гинекологической проблеме женщин репродуктивного возраста – синдрому поликистоза яичников (СПКЯ) и возможностям его фармакотерапии. Сложность в выборе фармакотерапии заболевания заключается в том, что необходимо учитывать все его клинические проявления, не ограничиваясь нарушениями менструального цикла и бесплодием. СПКЯ сопровождается, как правило, гирсутизмом, ожирением, снижением толерантности к глюкозе и другими проявлениями в различных системах органов, связанных с метаболическими нарушениями. Эти проявления существенно снижают качество жизни пациенток и также требуют фармакологической коррекции. В настоящее время первой линией препаратов в лечении СПКЯ остаются комбинированные оральные контрацептивы (КОК), которые используются женщинами уже на протяжении десятков лет, но обладают множественными нежелательными реакциями. Последнее служит поводом для поиска других методов фармакотерапии, обладающих высокой эффективностью и безопасностью. Одним из таких препаратов является пероральный сахароснижающий препарат метформин, доказавший свою эффективность в лечении СПКЯ. На стадии исследования находятся агонисты рецепторов глюкагоноподобного пептида-1, продолжается разработка тактики лечения СПКЯ с использованием сахароснижающих препаратов, обладающих антагонизмом к глюкагону. Расширение возможности выбора фармакотерапии, благодаря поиску новых более эффективных и безопасных лекарственных средств, и сочетание ее с другими методами лечения делают возможным контроль над СПКЯ с учетом индивидуальных особенностей пациенток.

The article is devoted to the actual gynecological problem of women of reproductive age-polycystic ovarian syndrome (PCOS) and the possibilities of its pharmacotherapy. Difficulties in choosing the treatment of the disease are the need to take into account all clinical manifestations, not limited to menstrual disorders and infertility. PCOS is usually accompanied by hirsutism, obesity, decreased glucose tolerance, and other manifestations in various organ systems associated with metabolic disorders. These manifestations significantly reduce the quality of life of patients and also require pharmacological correction. Currently, the first line of drugs in the treatment of PCOS remains combined oral contraceptives, which have been used by women for decades, but, unfortunately, have multiple adverse reactions. The latter is the reason for the search for other methods of pharmacotherapy that are highly effective and safe. Metformin is one these glucose-lowering drugs, which shows effectiveness in the treatment of PCOS. Drugs from such groups as glucagon-like peptide-1 receptor agonists are at the research stage, and the development of treatment tactics using glucose-lowering drugs that have antagonism to glucagon is continuing. Expanding the choice of pharmacotherapy, thanks to the search for new, more effective and safe drugs and combining it with other treatment methods, makes it possible to control PCOS taking into account the individual characteristics of patients.

синдром поликистоза яичниковкомбинированные оральные контрацептивыметформинагонисты рецепторов глюкагоноподобного пептида-1polycystic ovarian syndromecombined oral contraceptivesmetforminglucagon-like peptide-1 receptor agonistsReferencesAndrade V.H., Mata A.M., Borges R.S., Costa-Silva D.R., Martins L.M., Ferreira P.M., CunhaNunes L.C., Silva B.B. Current aspects of polycystic ovary syndrome: A literature review. Rev. Assoc. Med. Bras (1992). 2016;62(9):867–871. doi: 10.1590/1806-9282.62.09.867Andrade V.H., Mata A.M., Borges R.S., Costa-Silva D.R., Martins L.M., Ferreira P.M., CunhaNunes L.C., Silva B.B. Current aspects of polycystic ovary syndrome: A literature review. Rev. Assoc. Med. Bras (1992). 2016;62(9):867–871. doi: 10.1590/1806-9282.62.09.867Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 2000;85(7):2434–2438. doi: 10.1210/jcem.85.7.6682Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 2000;85(7):2434–2438. doi: 10.1210/jcem.85.7.6682Yildiz B.O., Bozdag G., Yapici Z., Esinler I., Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. Open. 2012;27(10): 3067–3073. doi: 10.1093/humrep/des232Yildiz B.O., Bozdag G., Yapici Z., Esinler I., Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. Open. 2012;27(10): 3067–3073. doi: 10.1093/humrep/des232Rosenfield R.L., Ehrmann D.A. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr. Rev. 2016;37(5):467–520. doi: 10.1210/er.2015-1104Rosenfield R.L., Ehrmann D.A. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr. Rev. 2016;37(5):467–520. doi: 10.1210/er.2015-1104Norman R.J., Dewailly D., Legro R.S., Hickey T.E. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697 doi: 10.1016/S0140-6736(07)61345-2Norman R.J., Dewailly D., Legro R.S., Hickey T.E. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697 doi: 10.1016/S0140-6736(07)61345-2Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98(12):4565–4592. doi: 10.1210/jc.2013-2350Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98(12):4565–4592. doi: 10.1210/jc.2013-2350Bednarska S., Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv. Clin. Exp. Med. 2017;26(2):359–367. doi: 10.17219/acem/59380Bednarska S., Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv. Clin. Exp. Med. 2017;26(2):359–367. doi: 10.17219/acem/59380Demissie M., Lazic M., Foecking E.M., Aird F., Dunaif A., Levine J.E. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am. J. Physiol Endocrinol. Metab. 2008;95(2):262–268. doi: 10.1152/ajpendo.90208.2008Demissie M., Lazic M., Foecking E.M., Aird F., Dunaif A., Levine J.E. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am. J. Physiol Endocrinol. Metab. 2008;95(2):262–268. doi: 10.1152/ajpendo.90208.2008Dumesic D.A., Oberfield S.E., Stener-Victorin E., Marshall J.C., Laven J.S., Legro R.S. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr. Rev. 2015;36(5):487–525. doi: /10.1210/er.2015-1018Dumesic D.A., Oberfield S.E., Stener-Victorin E., Marshall J.C., Laven J.S., Legro R.S. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr. Rev. 2015;36(5):487–525. doi: /10.1210/er.2015-1018Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 2004;89(6):2745– 2749. doi: 10.1210/jc.2003-032046Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 2004;89(6):2745– 2749. doi: 10.1210/jc.2003-032046Moran C., Tena G., Moran S., Ruiz P., Reyna R., Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol. Obstet. Invest. 2010;69(4):274–280. doi: 10.1159/000277640Moran C., Tena G., Moran S., Ruiz P., Reyna R., Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecol. Obstet. Invest. 2010;69(4):274–280. doi: 10.1159/000277640Diamanti-Kandarakis E., Kouli C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., Zapanti E.D., Bartzis M.I. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 1999;84(11):4006–4011. doi: 10.1210/jcem.84.11.6148Diamanti-Kandarakis E., Kouli C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., Zapanti E.D., Bartzis M.I. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 1999;84(11):4006–4011. doi: 10.1210/jcem.84.11.6148Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 2012;33(6):981–1030. doi: 10.1210/er.2011-1034Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 2012;33(6):981–1030. doi: 10.1210/er.2011-1034Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endoc. Rev. 1997;18(6):774–800. doi: 10.1210/edrv.18.6.0318Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endoc. Rev. 1997;18(6):774–800. doi: 10.1210/edrv.18.6.0318da Silva B.B., Lopes-Costa P.V., Rosal M.A., Pires C.G., dos Santos L.G., Gontijo J.A., Alencar A.P., de Jesus Simões M. Morphological and morphometric analysis of the adrenal cortex of androgenized female rats. Gynecol. Obstet. Invest. 2007;64(1):44–48. doi: 10.1159/000098956da Silva B.B., Lopes-Costa P.V., Rosal M.A., Pires C.G., dos Santos L.G., Gontijo J.A., Alencar A.P., de Jesus Simões M. Morphological and morphometric analysis of the adrenal cortex of androgenized female rats. Gynecol. Obstet. Invest. 2007;64(1):44–48. doi: 10.1159/000098956Peters H., Byskov A.G., Himelstein-Braw R., Faber M. Follicular growth: the basic event in the mouse and human ovary. J. Reprod. Fertil. 1975;45(3):559– 566. doi: 10.1530/jrf.0.0450559Peters H., Byskov A.G., Himelstein-Braw R., Faber M. Follicular growth: the basic event in the mouse and human ovary. J. Reprod. Fertil. 1975;45(3):559– 566. doi: 10.1530/jrf.0.0450559Fortune J.E., Cushman R.A., Wahl C.M., Kito S. The primordial to primary follicle transition. Mol. Cell Endocrinol. 2000;163(1-2):53–60. doi: 10.1016/s0303-7207(99)00240-3Fortune J.E., Cushman R.A., Wahl C.M., Kito S. The primordial to primary follicle transition. Mol. Cell Endocrinol. 2000;163(1-2):53–60. doi: 10.1016/s0303-7207(99)00240-3John G.B., Gallardo T.D., Shirley L.J., Castrillon D.H. Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. Dev. Biol. 2008;321(1):197–204. doi: 10.1016/j.ydbio.2008.06.017John G.B., Gallardo T.D., Shirley L.J., Castrillon D.H. Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. Dev. Biol. 2008;321(1):197–204. doi: 10.1016/j.ydbio.2008.06.017Reddy P., Liu L., Adhikari D., Jagarlamudi K., Rajareddy S., Shen Y., Du C., Tang W., Hämäläinen T., Peng S.L., Lan Z.J., Cooney A.J., Huhtaniemi I., Liu K. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2008;319(5863):611–613. doi: 10.1126/science.1152257Reddy P., Liu L., Adhikari D., Jagarlamudi K., Rajareddy S., Shen Y., Du C., Tang W., Hämäläinen T., Peng S.L., Lan Z.J., Cooney A.J., Huhtaniemi I., Liu K. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science. 2008;319(5863):611–613. doi: 10.1126/science.1152257Dumesic D.A., Richards J.S. Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril. 2013;100(1):23–38. doi: 10.1016/j.fertnstert.2013.02.01Dumesic D.A., Richards J.S. Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril. 2013;100(1):23–38. doi: 10.1016/j.fertnstert.2013.02.01Khashchenko E., Uvarova E., Vysokikh M., Ivanets T., Krechetova L., Tarasova N., Sukhanova I., Mamedova F., Borovikov P., Balashov I., Sukhikh G. The relevant hormonal levels and diagnostic features of polycystic ovary syndrome in adolescents. J. Clin. Med. 2020;9(6):1831. doi: 10.3390/jcm9061831Khashchenko E., Uvarova E., Vysokikh M., Ivanets T., Krechetova L., Tarasova N., Sukhanova I., Mamedova F., Borovikov P., Balashov I., Sukhikh G. The relevant hormonal levels and diagnostic features of polycystic ovary syndrome in adolescents. J. Clin. Med. 2020;9(6):1831. doi: 10.3390/jcm9061831Balen A.H., Rutherford A.J. Managing anovulatory infertility and polycystic ovary syndrome. BMJ. 2007;335(7621):663–666. doi: 10.1136/bmj.39335.462303.80Balen A.H., Rutherford A.J. Managing anovulatory infertility and polycystic ovary syndrome. BMJ. 2007;335(7621):663–666. doi: 10.1136/bmj.39335.462303.80Moutos D., Smith S., Zacur H. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Contraception. 1995;52(2):105–109. doi: 10.1016/s0010-7824(95)00137-9Moutos D., Smith S., Zacur H. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Contraception. 1995;52(2):105–109. doi: 10.1016/s0010-7824(95)00137-9Willis D.S., Watson H., Mason H.D., Galea R., Brincat M., Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J. Clin. Endocrinol. Metab. 1998;83(11):3984–3991. doi: 10.1210/jcem.83.11.5232Willis D.S., Watson H., Mason H.D., Galea R., Brincat M., Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J. Clin. Endocrinol. Metab. 1998;83(11):3984–3991. doi: 10.1210/jcem.83.11.5232Magoffin D.A. Ovarian theca cell. Int. J. Biochem. Cell Biol. 2005;37(7):1344–1349. doi: 10.1016/j.biocel.2005.01.016Magoffin D.A. Ovarian theca cell. Int. J. Biochem. Cell Biol. 2005;37(7):1344–1349. doi: 10.1016/j.biocel.2005.01.016Edson M.A., Nagaraja A.K., Matzuk M.M. The mammalian ovary from genesis to revelation. Endocr. Rev. 2009;30(6):624–712. doi: 10.1210/er.2009-0012Edson M.A., Nagaraja A.K., Matzuk M.M. The mammalian ovary from genesis to revelation. Endocr. Rev. 2009;30(6):624–712. doi: 10.1210/er.2009-0012Barbieri R.L., Makris A., Randall R.W., Daniels G., Kistner R.W., Ryan K.J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab. 1986;62(5):904–910. doi: /10.1210/jcem-62-5-904Barbieri R.L., Makris A., Randall R.W., Daniels G., Kistner R.W., Ryan K.J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab. 1986;62(5):904–910. doi: /10.1210/jcem-62-5-904Conway G.S., Jacobs H.S., Holly J.M., Wass J.A. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 1990;33(5):593–603. doi: 10.1111/j.1365-2265.1990.tb03897Conway G.S., Jacobs H.S., Holly J.M., Wass J.A. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 1990;33(5):593–603. doi: 10.1111/j.1365-2265.1990.tb03897Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 2003;163(4):427–436. doi: 10.1001/archinte.163.4.427Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch. Intern. Med. 2003;163(4):427–436. doi: 10.1001/archinte.163.4.427Legro R.S., Kunselman A.R., Dodson W.C., Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 1999;84(1):165–169. doi: 10.1210/jcem.84.1.5393Legro R.S., Kunselman A.R., Dodson W.C., Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 1999;84(1):165–169. doi: 10.1210/jcem.84.1.5393Mani H., Levy M.J., Davies M.J., Morris D.H., Gray L.J., Bankart J., Blackledge H., Khunti K., Howlett T.A. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin. Endocrinol. (Oxf). 2013;373(22):2117–2128. doi: 10.1111/cen.12068Mani H., Levy M.J., Davies M.J., Morris D.H., Gray L.J., Bankart J., Blackledge H., Khunti K., Howlett T.A. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin. Endocrinol. (Oxf). 2013;373(22):2117–2128. doi: 10.1111/cen.12068de Groot P.C., Dekkers O.M., Romijn J.A., Dieben S.W., Helmerhorst F.M. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum. Reprod. Update. 2011;17(4):495–500. doi: 10.1093/humupd/dmr001de Groot P.C., Dekkers O.M., Romijn J.A., Dieben S.W., Helmerhorst F.M. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum. Reprod. Update. 2011;17(4):495–500. doi: 10.1093/humupd/dmr001Синдром поликистоза яичников. Клинические рекомендации. 2016. Режим доступа: https://rae-org.ru/system/files/documents/pdf/kr258_sindrom_polikistoza_yaichnikov.pdf Polycystic ovary syndrome. Clinical guidelines. 2016. Available at: https://rae-org.ru/system/files/documents/pdf/kr258_sindrom_polikistoza_yaichnikov.pdf [In Russian].Синдром поликистоза яичников. Клинические рекомендации. 2016. Режим доступа: https://rae-org.ru/system/files/documents/pdf/kr258_sindrom_polikistoza_yaichnikov.pdf Polycystic ovary syndrome. Clinical guidelines. 2016. Available at: https://rae-org.ru/system/files/documents/pdf/kr258_sindrom_polikistoza_yaichnikov.pdf [In Russian].Tay C.T., Joham A.E., Hiam D.S., Gadalla M.A., Pundir J., Thangaratinam S., Teede H.J., Moran L.J. Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Clin. Endocrinol. (Oxf). 2018;89(5):35–553. doi: 10.1111/cen.1375Tay C.T., Joham A.E., Hiam D.S., Gadalla M.A., Pundir J., Thangaratinam S., Teede H.J., Moran L.J. Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Clin. Endocrinol. (Oxf). 2018;89(5):35–553. doi: 10.1111/cen.1375Menshawy A., Ismail A., Abdel-Maboud M., El-Din A.A., Elgebaly A., Gadelkarim M., Bahbah E.I., Abdelghany M.F., Samy A., Abbas A.M. Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials. J. Gynecol. Obstet. Hum. Reprod. 2019;48(9):763–770. doi: 10.1016/j.jogoh.2019.03.025Menshawy A., Ismail A., Abdel-Maboud M., El-Din A.A., Elgebaly A., Gadelkarim M., Bahbah E.I., Abdelghany M.F., Samy A., Abbas A.M. Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials. J. Gynecol. Obstet. Hum. Reprod. 2019;48(9):763–770. doi: 10.1016/j.jogoh.2019.03.025Schlesselman J.J. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner’s guide to meta-analysis. Hum. Reprod. 1997;12(9):1851–1863. doi: 10.1093/humrep/12.9.1851Schlesselman J.J. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner’s guide to meta-analysis. Hum. Reprod. 1997;12(9):1851–1863. doi: 10.1093/humrep/12.9.1851Manson J.E., Rimm E.B., Colditz G.A., Willett W.C., Nathan D.M., Arky R.A., Rosner B., Hennekens C.H., Speizer F.E., Stampfer M.J. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann. Epidemiol. 1992;2(5):665–673 doi: 10.1016/1047-2797(92)90011-eManson J.E., Rimm E.B., Colditz G.A., Willett W.C., Nathan D.M., Arky R.A., Rosner B., Hennekens C.H., Speizer F.E., Stampfer M.J. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann. Epidemiol. 1992;2(5):665–673 doi: 10.1016/1047-2797(92)90011-eRabe T., Luxembourg B., Ludwig M., Dinger J., Bauersachs R., Rott H., Mueck A.O., Albring C. Contraception and thrombophilia – a statement from the German Society for Gynecological Endocrinology and Reproductive Medicine and the Professional Association of German Gynaecologists. J. Reproduktions Med. Endokrinol. 2011;8(1):126–167. doi: 10.18370/2309-4117.2019.45.52-56Rabe T., Luxembourg B., Ludwig M., Dinger J., Bauersachs R., Rott H., Mueck A.O., Albring C. Contraception and thrombophilia – a statement from the German Society for Gynecological Endocrinology and Reproductive Medicine and the Professional Association of German Gynaecologists. J. Reproduktions Med. Endokrinol. 2011;8(1):126–167. doi: 10.18370/2309-4117.2019.45.52-56Hickson S.S., Miles K.L., McDonnell B.J., Cockcroft J.R., Wilkinson I.B., McEniery C.M., ENIGMA Study Investigators. Use of the oral contraceptive pill is associated with increased large artery stiffness in young women: the ENIGMA study. J. Hypertens. 2011;29(6):1155–1159. doi: 10.1097/HJH.0b013e328346a5afHickson S.S., Miles K.L., McDonnell B.J., Cockcroft J.R., Wilkinson I.B., McEniery C.M., ENIGMA Study Investigators. Use of the oral contraceptive pill is associated with increased large artery stiffness in young women: the ENIGMA study. J. Hypertens. 2011;29(6):1155–1159. doi: 10.1097/HJH.0b013e328346a5afAmiri M., Ramezani-Tehrani F., Nahidi F., Kabir A., Azizi F. Comparing the effects of combined oral contraceptives containing progestins with low androgenic and antiandrogenic activities on the hypothalamic-pituitary-gonadal axis in patients with polycystic ovary syndrome: systematic review and meta-analysis. JMIR Res. Protoc. 2018;7(4):e113. doi: 10.2196/resprot.9024Amiri M., Ramezani-Tehrani F., Nahidi F., Kabir A., Azizi F. Comparing the effects of combined oral contraceptives containing progestins with low androgenic and antiandrogenic activities on the hypothalamic-pituitary-gonadal axis in patients with polycystic ovary syndrome: systematic review and meta-analysis. JMIR Res. Protoc. 2018;7(4):e113. doi: 10.2196/resprot.9024Azziz R. The evaluation and management of hirsutism. Obstet. Gynecol. 2003;101(5 Pt 1):995–1007. doi: 10.1016/s0029-7844(02)02725-4Azziz R. The evaluation and management of hirsutism. Obstet. Gynecol. 2003;101(5 Pt 1):995–1007. doi: 10.1016/s0029-7844(02)02725-4Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K., Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol. 1995;15(7):821–826. doi: 10.1161/01.atv.15.7.821Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K., Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol. 1995;15(7):821–826. doi: 10.1161/01.atv.15.7.821Watanabe R.M., Azen C.G., Roy S., Perlman J.A., Bergman R.N. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J. Clin. Endocrinol. Metab. 1994;79(5):1277– 1283. doi: 10.1210/jcem.79.5.7962320Watanabe R.M., Azen C.G., Roy S., Perlman J.A., Bergman R.N. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J. Clin. Endocrinol. Metab. 1994;79(5):1277– 1283. doi: 10.1210/jcem.79.5.7962320Plewig G., Cunliffe W.J., Binder N., Höschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80(1):25–33. doi: 10.1016/j.contraception.2009.02.016Plewig G., Cunliffe W.J., Binder N., Höschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial. Contraception. 2009;80(1):25–33. doi: 10.1016/j.contraception.2009.02.016Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., Schünemann H.J., GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336 (7650): 924–926. doi: 10.1136/bmj.39489.470347Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., Schünemann H.J., GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336 (7650): 924–926. doi: 10.1136/bmj.39489.470347Jung-Hoffmann C., Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am. J. Obstet. Gynecol. 1987;156(53):199–203. doi: 10.1016/0002-9378(87)90238-9Jung-Hoffmann C., Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am. J. Obstet. Gynecol. 1987;156(53):199–203. doi: 10.1016/0002-9378(87)90238-9Winkler U.H., Sudik R. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception. 2009;79(1):15– 23. doi: 10.1016/j.contraception.2008.08.011Winkler U.H., Sudik R. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception. 2009;79(1):15– 23. doi: 10.1016/j.contraception.2008.08.011Cibula D., Fanta M., Vrbikova J., Stanicka S., Dvorakova K., Hill M., Skrha J., Zivny J., Skrenkova J. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum. Reprod. 2005;20(1):180–184. doi: 10.1093/humrep/deh588Cibula D., Fanta M., Vrbikova J., Stanicka S., Dvorakova K., Hill M., Skrha J., Zivny J., Skrenkova J. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum. Reprod. 2005;20(1):180–184. doi: 10.1093/humrep/deh588Franks S. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin. Endocrinol. (Oxf). 2011;74(2):148–151. doi: 10.1111/j.1365-2265.2010.03934.xFranks S. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? Clin. Endocrinol. (Oxf). 2011;74(2):148–151. doi: 10.1111/j.1365-2265.2010.03934.xVelazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43(5):647–654. doi: 10.1016/0026-0495(94)90209-7Velazquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43(5):647–654. doi: 10.1016/0026-0495(94)90209-7Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–10273. doi: 10.1158/0008-5472.CAN-06-1500Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–10273. doi: 10.1158/0008-5472.CAN-06-1500Unlühizarci K., Keleştimur F., Bayram F., Sahin Y., Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 1999;51(2):231–236. doi: 10.1046/ j.1365-2265.1999.00786Unlühizarci K., Keleştimur F., Bayram F., Sahin Y., Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 1999;51(2):231–236. doi: 10.1046/ j.1365-2265.1999.00786Crave J.C., Fimbel S., Lejeune H., Cugnardey N., Déchaud H., Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J. Clin. Endocrinol. Metab. 1995;80(7):2057–2062. doi: 10.1210/jcem.80.7.7608255Crave J.C., Fimbel S., Lejeune H., Cugnardey N., Déchaud H., Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J. Clin. Endocrinol. Metab. 1995;80(7):2057–2062. doi: 10.1210/jcem.80.7.7608255Crosignani P.G., Colombo M., Vegetti W., Somigliana E., Gessati A., Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum. Reprod. 2003;18(9):1928–1932. doi: 10.1093/humrep/deg367Crosignani P.G., Colombo M., Vegetti W., Somigliana E., Gessati A., Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum. Reprod. 2003;18(9):1928–1932. doi: 10.1093/humrep/deg367Clark A.M., Ledger W., Galletly C., Tomlinson L., Blaney F., Wang X., Norman R.J. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. 1995;10(10):2705–2712. doi: 10.1093/oxfordjournals.humrep.a135772Clark A.M., Ledger W., Galletly C., Tomlinson L., Blaney F., Wang X., Norman R.J. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. 1995;10(10):2705–2712. doi: 10.1093/oxfordjournals.humrep.a135772Wang A., Mo T., Li Q., Shen C., Liu M. The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. Endocrine. 2019;64(2):220– 232. doi: 10.1007/s12020-019-01860-wWang A., Mo T., Li Q., Shen C., Liu M. The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. Endocrine. 2019;64(2):220– 232. doi: 10.1007/s12020-019-01860-wKujawska-Luczak M., Szulinska M., Skrypnik D., Musialik K., Swora-Cwynar E., Kregielska-Narozna M., Markuszewski L., Grzymislawska M., Bogdanski P. The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance. J. Physiol. Pharmacol. 2018;69(5):738–745. doi: 10.26402/jpp.2018.5.08Kujawska-Luczak M., Szulinska M., Skrypnik D., Musialik K., Swora-Cwynar E., Kregielska-Narozna M., Markuszewski L., Grzymislawska M., Bogdanski P. The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance. J. Physiol. Pharmacol. 2018;69(5):738–745. doi: 10.26402/jpp.2018.5.08McDuffie J.R., Calis K.A., Booth S.L., Uwaifo G.I., Yanovski J.A. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814–822. doi: 10.1592/phco.22.11.814.33627McDuffie J.R., Calis K.A., Booth S.L., Uwaifo G.I., Yanovski J.A. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814–822. doi: 10.1592/phco.22.11.814.33627Escobar-Morreale H.F., Botella-Carretero J.I., Alvarez-Blasco F., Sancho J., San Millán J.L. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 2005;90(12):6364–6369. doi: 10.1210/jc.2005-1490Escobar-Morreale H.F., Botella-Carretero J.I., Alvarez-Blasco F., Sancho J., San Millán J.L. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 2005;90(12):6364–6369. doi: 10.1210/jc.2005-1490Cena H., Chiovato L., Nappi R.E. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J. Clin. Endocrinol. Metab. 2020;105(8):2695–2709. doi: 10.1210/clinem/dgaa285Cena H., Chiovato L., Nappi R.E. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J. Clin. Endocrinol. Metab. 2020;105(8):2695–2709. doi: 10.1210/clinem/dgaa285Coskun T., Sloop K.W., Loghin C., Alsina-Fernandez J., Urva S., Bokvist K.B., Cui X., Briere D.A., Cabrera O., Roell W.C., Kuchibhotla U., Moyers J.S., Benson C.T., Gimeno R.E., D’Alessio D.A., Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol. Metab. 2018;(18):3–14. doi: 10.1016/j.molmet.2018.09.009Coskun T., Sloop K.W., Loghin C., Alsina-Fernandez J., Urva S., Bokvist K.B., Cui X., Briere D.A., Cabrera O., Roell W.C., Kuchibhotla U., Moyers J.S., Benson C.T., Gimeno R.E., D’Alessio D.A., Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol. Metab. 2018;(18):3–14. doi: 10.1016/j.molmet.2018.09.009Frias J.P., Bastyr E.J., Vignati L., Tschöp M.H., Schmitt C., Owen K., Christensen R.H., DiMarchi R.D. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell. Metab. 2017;26(2):343–352. doi: 10.1016/j.cmet.2017.07.011Frias J.P., Bastyr E.J., Vignati L., Tschöp M.H., Schmitt C., Owen K., Christensen R.H., DiMarchi R.D. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell. Metab. 2017;26(2):343–352. doi: 10.1016/j.cmet.2017.07.011Henderson S.J., Konkar A., Hornigold D.C., Trevaskis J.L., Jackson R., Fritsch Fredin M., Jansson-Löfmark R., Naylor J., Rossi A., Bednarek M.A., Bhagroo N., Salari H., Will S., Oldham S., Hansen G., Feigh M., Klein T., Grimsby J., Maguire S., Jermutus L., Rondinone C.M., Coghlan M.P. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 2016;18(12):1176–1190. doi: 10.1111/dom.12735Henderson S.J., Konkar A., Hornigold D.C., Trevaskis J.L., Jackson R., Fritsch Fredin M., Jansson-Löfmark R., Naylor J., Rossi A., Bednarek M.A., Bhagroo N., Salari H., Will S., Oldham S., Hansen G., Feigh M., Klein T., Grimsby J., Maguire S., Jermutus L., Rondinone C.M., Coghlan M.P. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 2016;18(12):1176–1190. doi: 10.1111/dom.12735Zhou J., Cai X., Huang X., Dai Y., Sun L., Zhang B., Yang B., Lin H., Huang W., Qian H. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects. Eur. J. Med. Chem. 2017;138:1158–1169. doi: 10.1016/j.ejmech.2017.07.046Zhou J., Cai X., Huang X., Dai Y., Sun L., Zhang B., Yang B., Lin H., Huang W., Qian H. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects. Eur. J. Med. Chem. 2017;138:1158–1169. doi: 10.1016/j.ejmech.2017.07.046Müller T.D., Finan B., Clemmensen C., DiMarchi R.D., Tschöp M.H. The new biology and pharmacology of glucagon. Physiol. Rev. 2017;97(2):721–766. doi: 10.1152/physrev.00025.2016Müller T.D., Finan B., Clemmensen C., DiMarchi R.D., Tschöp M.H. The new biology and pharmacology of glucagon. Physiol. Rev. 2017;97(2):721–766. doi: 10.1152/physrev.00025.2016Garthe I., Raastad T., Refsnes P.E., Koivisto A., Sundgot-Borgen J. Effect of two different weight-loss rates on body composition and strength and powerrelated performance in elite athletes. Int. J. Sport Nutr. Exerc. Metab. 2011;21(2):97–104. doi: 10.1123/ijsnem.21.2.97Garthe I., Raastad T., Refsnes P.E., Koivisto A., Sundgot-Borgen J. Effect of two different weight-loss rates on body composition and strength and powerrelated performance in elite athletes. Int. J. Sport Nutr. Exerc. Metab. 2011;21(2):97–104. doi: 10.1123/ijsnem.21.2.97Vuylsteke V., Chastain L.M., Maggu G.A., Brown C. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs RD. 2015;15(3):227–232. doi: 10.1007/s40268-015-0099-3Vuylsteke V., Chastain L.M., Maggu G.A., Brown C. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs RD. 2015;15(3):227–232. doi: 10.1007/s40268-015-0099-3Yaribeygi H., Maleki M., Sathyapalan T., Jamialahmadi T., Sahebkar A. Molecular mechanisms by which imeglimin improves glucose homeostasis. J. Diabetes Res. 2020;(2):1–5. doi: 10.1155/2020/8768954Yaribeygi H., Maleki M., Sathyapalan T., Jamialahmadi T., Sahebkar A. Molecular mechanisms by which imeglimin improves glucose homeostasis. J. Diabetes Res. 2020;(2):1–5. doi: 10.1155/2020/8768954Paoli A., Mancin L., Giacona M.C., Bianco A., Caprio M. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. J. Transl. Med. 2020;18(1):104. doi: 10.1186/s12967-020-02277-0Paoli A., Mancin L., Giacona M.C., Bianco A., Caprio M. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. J. Transl. Med. 2020;18(1):104. doi: 10.1186/s12967-020-02277-0Jensterle M., Kravos N.A., Ferjan S., Goricar K., Dolzan V., Janez A. Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocr. Connect. 2020;9(1):44–54. doi: 10.1530/EC-19-0449Jensterle M., Kravos N.A., Ferjan S., Goricar K., Dolzan V., Janez A. Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. Endocr. Connect. 2020;9(1):44–54. doi: 10.1530/EC-19-0449Hallakou-Bozec S., Vial G., Kergoat M., Fouqueray P., Bolze S., Borel A.L., Fontaine E., Moller D.E. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes. Metab. 2021;23(3):664–673. doi: 10.1111/dom.14277Hallakou-Bozec S., Vial G., Kergoat M., Fouqueray P., Bolze S., Borel A.L., Fontaine E., Moller D.E. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes. Metab. 2021;23(3):664–673. doi: 10.1111/dom.14277Papaetis G.S., Filippou P.K., Constantinidou K.G., Stylianou C.S. Liraglutide: New perspectives for the treatment of polycystic ovary syndrome. Clin. Drug Investig. 2020;40(8):695–713. doi: 10.1007/s40261-020-00942-2Papaetis G.S., Filippou P.K., Constantinidou K.G., Stylianou C.S. Liraglutide: New perspectives for the treatment of polycystic ovary syndrome. Clin. Drug Investig. 2020;40(8):695–713. doi: 10.1007/s40261-020-00942-2Abdalla M.A., Deshmukh H., Atkin S., Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther. Adv. Endocrinol. Metab. 2020; 2042018820938305. doi: 10.1177/2042018820938305Abdalla M.A., Deshmukh H., Atkin S., Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther. Adv. Endocrinol. Metab. 2020; 2042018820938305. doi: 10.1177/2042018820938305

The authors declare that there are no conflicts of interest present.